Evidence item

The study reports 100% bioactivity after more than two months at 37 °C for solid-state formulations representing SM-102 and ALC-0315 LNP compositions. MEASUREMENT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 25847

Source: Accelerated discovery of thermostable mRNA–lipid nanoparticle vaccines using data-efficient AI · locator {} · excerpt hash sha256:18cf5c9ee328859c510d4d85beeeb5409b657edec74fe5556b2951da1169047c

We stabilized mRNA vaccines with two clinically relevant LNPs representative of the Moderna (SM-102-based) and Pfizer-BioNTech (ALC-0315-based) compositions into solid-state formulations that retained 100% bioactivity after storage at 37 °C for more than 2 months.